

CLAIM AMENDMENTS

Claims 1 through 70 (canceled)

1 71. (New) A liquid crystal gel for use in the manufacture
2 of transdermal pharmaceutical compositions and healing cosmetics,
3 which comprises:

| | |
|--|--------------------|
| 4 Polyoxyethylene-glyceryl-trioleate | 26.7 - 40.0 %, |
| 5 Propylene-glycol | 13.3 - 20.0 %, |
| 6 Isopropyl myristate | 5.0 - 35.0 %, |
| 7 Ethanol | 0.01 - 10.0 % |
| 8 Benzyl alcohol | 0.5 - 1.5 %, |
| 9 a hyaluronic acid salt or complex | 0.01 - 2.00 %, and |
| 10 Purified water | 12.5 to 26.5% . |

1 72. (New) The liquid crystal gel defined in claim 71 wherein
2 the hyaluronic acid salt or complex is sodium hyaluronate.

1 73. (New) The liquid crystal gel defined in claim 71
2 wherein the hyaluronic acid salt or complex is zinc hyaluronic acid
3 complex.

1 74. (New) The liquid crystal gel defined in claim 71
2 wherein the ratio of polyoxyethylene-glyceryl-trioleate and propylene-
3 glycol is 2:1.

1 75. (New) The liquid crystal gel defined in claim 71 which
2 comprises:

| | |
|------------------------------------|--------------------|
| Polyoxyethylene-glyceryl-trioleate | 30.0 - 35.0 %, |
| Propylene-glycol | 15.0 - 18.0 %, |
| Isopropyl myristate | 17.0 - 20.0 %, |
| Ethanol | 4.0 - 6.0 % |
| Benzyl alcohol | 0.7 - 1.3 %, |
| a hyaluronic acid salt or complex | 0.05 - 0.15 %, and |
| Purified water | 20.0 to 25.0% |

1 76. (New) The liquid crystal gel defined in claim 75
2 wherein the hyaluronic acid salt or complex is sodium hyaluronate
3 having a mean molecular weight from 580,000 to 620,000 or from
4 1,350,000 to 1,400,000.

1 77. (New) The liquid crystal gel defined in claim 75
2 wherein the hyaluronic acid salt or complex is zinc hyaluronic acid
3 complex having a mean molecular weight from 600,000 to 650,000..

1 78. (New) The liquid crystal gel defined in claim 76 which
2 comprises:

| | |
|------------------------------------|---------|
| Polyoxyethylene-glyceryl-trioleate | 33.3 %, |
| Propylene-glycol | 16.7 %, |
| Isopropyl myristate | 19.0 %, |
| Ethanol | 5.0 % |

7 Benzyl alcohol 1.0%,
8 Sodium hyaluronate 0.1 %, and
9 Supplemented with purified water ad 100% .

1 79. (New) The liquid crystal gel defined in claim 77 which
2 comprises:

3 Polyoxyethylene-glyceryl-trioleate 33.3 %,
4 Propylene-glycol 16.7 %,
5 Isopropyl myristate 19.0 %,
6 Ethanol 5.0 %
7 Benzyl alcohol 1.0%,
8 Zinc hyaluronic acid complex 0.1 %, and
9 Supplemented with purified water ad 100%

1 80. (new) A transdermal pharmaceutical composition as a
2 liquid crystal gel, which consists essentially of:

3 (a) an estrogen component; and
4 (b) a progestin component, as therapeutically effective
5 ingredients wherein said estrogen component and said progestin
6 component are included in a therapeutically effective amount
7 sufficient for hormone replacement therapy; and

8 (c) a liquid crystal gel which contains the therapeutically
9 active ingredients, said liquid crystal gel consisting essentially of:

10 Polyoxyethylene-glyceryl-trioleate 26.7 - 40.0 %,
11 Propylene-glycol 13.3 - 20.0 %,

| | | |
|----|-----------------------------------|--------------------|
| 12 | Isopropyl myristate | 5.0 - 35.0 %, |
| 13 | Ethanol | 0.01 - 10.0 % |
| 14 | Benzyl alcohol | 0.5 - 1.5 %, |
| 15 | a hyaluronic acid salt or complex | 0.01 - 2.00 %, and |
| 16 | Purified water | 12.5 to 26.5% . |

1 81. (New) The transdermal pharmaceutical composition as
2 a liquid crystal gel defined in claim 80 wherein the estrogen
3 component is estradiol.

1 82. (New) The transdermal pharmaceutical composition as
2 a liquid crystal gel defined in claim 80 wherein the progestin
3 compound is gestodene.

1 83. (New) The transdermal pharmaceutical composition as
2 a liquid crystal gel defined in claim 80 wherein the progestin
3 compound is etonogestrel.

1 84. (New) The transdermal pharmaceutical composition as
2 a liquid crystal gel defined in claim 80 wherein the progestin
3 compound is levonorgestrel.

1 85. (New) A method of treating a patient for moderate to
2 severe vasomotor symptoms, as well as hot flashes, nocturnal
3 sweating, and palpitation due to post-menopausal estrogen

4 deficiency, which comprises the step of transdermally administering
5 to the skin of the patient, a therapeutically effective amount of
6 the transdermal pharmaceutical composition defined in claim 80.

1 86. (New) A transdermal pharmaceutical composition as a
2 liquid crystal gel, which consists essentially of:

3 (a) at least one therapeutically active ingredient and

4 (b) a liquid crystal gel which contains the at least one
5 therapeutically active ingredient, said liquid crystal gel
6 consisting essentially of:

7 Polyoxyethylene-glyceryl-trioleate 26.7 - 40.0 %,

8 Propylene-glycol 13.3 - 20.0 %,

9 Isopropyl myristate 5.0 - 35.0 %,

10 Ethanol 0.01 - 10.0 %

11 Benzyl alcohol 0.5 - 1.5 %,

12 a hyaluronic acid salt or complex 0.01 - 2.00 %, and

13 Purified water 12.5 to 26.5% .

1 87. (New) The transdermal pharmaceutical composition as
2 a liquid crystal gel defined in claim 86 wherein the
3 therapeutically active ingredient is ondansetron.

1 88. (New) The transdermal pharmaceutical composition as
2 a liquid crystal gel defined in claim 86 wherein the
3 therapeutically active ingredient is terbinafine.

1 89. (New) The transdermal pharmaceutical composition as
2 a liquid crystal gel defined in claim 86 wherein the
3 therapeutically active ingredient is fluconazole.

1 90. (New) The transdermal pharmaceutical composition as
2 a liquid crystal gel defined in claim 86 wherein the
3 therapeutically active ingredient is metronidazole.

1 91. (New) The transdermal pharmaceutical composition as
2 a liquid crystal gel defined in claim 86 wherein the
3 therapeutically active ingredient is fentanyl.

1 92. (New) The transdermal pharmaceutical composition as
2 a liquid crystal gel defined in claim 86 wherein the
3 therapeutically active ingredient is nandrolone decanoate.

1 93. (New) The transdermal pharmaceutical composition as
2 a liquid crystal gel defined in claim 86 wherein the
3 therapeutically active ingredient is nestorone.

1 94. (New) The transdermal pharmaceutical composition as
2 a liquid crystal gel defined in claim 86 wherein the
3 therapeutically active ingredient is norethisterone.

1 95. (New) The transdermal pharmaceutical composition as
2 a liquid crystal gel defined in claim 86 wherein the
3 therapeutically active ingredient is eperisone.

1 96. (New) The transdermal pharmaceutical composition as
2 a liquid crystal gel defined in claim 86 wherein the
3 therapeutically active ingredient is tolperisone.

1 97. (New) The transdermal pharmaceutical composition as
2 a liquid crystal gel defined in claim 86 wherein the
3 therapeutically active ingredient is vincopetine.

1 98. (New) The transdermal pharmaceutical composition as
2 a liquid crystal gel defined in claim 86 wherein the
3 therapeutically active ingredient is ketamine.

1 99. (New) The transdermal pharmaceutical composition as
2 a liquid crystal gel defined in claim 86 wherein the
3 therapeutically active ingredient is vincristine.

1 100. (New) The transdermal pharmaceutical composition as
2 a liquid crystal gel defined in claim 86 wherein the
3 therapeutically active ingredient is vinblastine.